

---

## **Date of AGM and Closing Date for Director Nominations**

**Adelaide, Australia, 30 September 2021** – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that in accordance with ASX Listing Rule 3.13.1, Nova Eye Medical advises that the Annual General Meeting of the Company will be held on Wednesday, 24 November 2021 at 11.30am Australian Central Daylight Time (Adelaide Time).

A notice of meeting for the Annual General Meeting is being prepared by the Company and will be announced to ASX and provided to Shareholders in October 2021.

An item of business at the Annual General Meeting will be the election of Directors. The closing date for the receipt of nominations for the election of Directors is 13 October 2021.

Any nominations must be received no later than 5.00pm (Adelaide time) on 13 October 2021 at the Company's registered office.

***This release dated 30 September 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.***

**– ENDS –**

### **Company**

Tom Spurling  
Director  
Nova Eye Medical Limited  
W +61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

### **Investors**

Dr. Tom Duthy  
Investor Relations & Corporate Development  
Nova Eye Medical Limited  
W +61 402 493 727  
[tduthy@nova-eye.com](mailto:tduthy@nova-eye.com)

### **Company**

Kate Hunt  
Head of Marketing  
Nova Eye Medical Limited  
W +61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

---

## **ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)